DolPHIN-2 Study team's response to WHO's statement on the safety of dolutegravir in pregnancy

WHO released a statement on 18 May 2018 relating to a potential safety issue affecting women living with HIV using dolutegravir at the time of conception. The DolPHIN-2 study team has carefully reviewed our statement and prepared a response to the statement in relation to the DolPHIN-2 clinical triall. You can read our response here


To sign up to our newsletter, please enter your details below: